Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H31FO6 |
Molecular Weight | 422.487 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)CC[C@]34C
InChI
InChIKey=SYWHXTATXSMDSB-GSLJADNHSA-N
InChI=1S/C23H31FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h10,16-18,27,29H,4-9,11-12H2,1-3H3/t16-,17-,18-,20-,21-,22-,23-/m0/s1
Molecular Formula | C23H31FO6 |
Molecular Weight | 422.487 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.2ndchance.info/addison's-florinef.pdf
Curator's Comment: description was created based on several sources, including
http://www.2ndchance.info/addison's-florinef.pdf
Fludrocortisone acetate (approved as Florinef) is a synthetic adrenocortical steroid possessing very potent mineralcorticoid properties and high glucocorticoid activity. Main indications are Partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt losing adrenogenital syndrome.
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01634a101
Curator's Comment: refernce was retrived from https://www.researchgate.net/publication/284208027_Fludrocortisone_Acetate
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P22199 Gene ID: 25672.0 Gene Symbol: Nr3c2 Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/611629 |
1.07 nM [Kd] | ||
Target ID: P08235 Gene ID: 4306.0 Gene Symbol: NR3C2 Target Organism: Homo sapiens (Human) |
|||
Target ID: P06536 Gene ID: 24413.0 Gene Symbol: Nr3c1 Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/611629 |
|||
Target ID: P04150 Gene ID: 2908.0 Gene Symbol: NR3C1 Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FLORINEF Approved UseFludrocortisone acetate tablets USP, 0.1 mg are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. Launch Date1955 |
|||
Primary | FLORINEF Approved UseFludrocortisone acetate tablets USP, 0.1 mg are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. Launch Date1955 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1241.1 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25611194 |
0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUDROCORTISONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.19 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27416887 |
50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: |
FLUDROCORTISONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3275.8 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25611194 |
0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUDROCORTISONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.25 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27416887 |
50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: |
FLUDROCORTISONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.57 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25611194 |
0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUDROCORTISONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27416887 |
50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: |
FLUDROCORTISONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25611194 |
0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUDROCORTISONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
0.3 mg 1 times / day multiple, oral Highest studied dose Dose: 0.3 mg, 1 times / day Route: oral Route: multiple Dose: 0.3 mg, 1 times / day Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: anuric patients with symptomatic hypotension Population Size: 5 Sources: |
Other AEs: Serum potassium decreased, Rise in blood pressure... Other AEs: Serum potassium decreased (5 patients) Sources: Rise in blood pressure (5 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Rise in blood pressure | 5 patients | 0.3 mg 1 times / day multiple, oral Highest studied dose Dose: 0.3 mg, 1 times / day Route: oral Route: multiple Dose: 0.3 mg, 1 times / day Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: anuric patients with symptomatic hypotension Population Size: 5 Sources: |
Serum potassium decreased | 5 patients | 0.3 mg 1 times / day multiple, oral Highest studied dose Dose: 0.3 mg, 1 times / day Route: oral Route: multiple Dose: 0.3 mg, 1 times / day Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: anuric patients with symptomatic hypotension Population Size: 5 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Potassium-lowering effect of mineralocorticoid therapy in patients undergoing hemodialysis. | 2002 |
|
[Primary adrenal insufficiency due to autoimmune adrenalitis]. | 2002 Aug |
|
Outcomes for laparoscopic bilateral adrenalectomy. | 2002 Aug |
|
Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. | 2002 Aug |
|
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. | 2002 Aug 21 |
|
Reducing mortality in sepsis: new directions. | 2002 Dec |
|
Chronic unexplained fatigue. | 2002 Dec |
|
Treatment of orthostatic hypotension. | 2002 Dec |
|
Salt losing nephropathy simulating congenital adrenal hyperplasia in an infant. | 2002 Jul |
|
A footnote on the origin of fluorosteroids. | 2002 Jul |
|
Screening and diagnosis of primary aldosteronism. | 2002 Jul-Aug |
|
Yoghurt biotherapy: contraindicated in immunosuppressed patients? | 2002 Jun |
|
Cortisol replacement for severe sepsis and septic shock: what should I do? | 2002 Jun |
|
Orthostatic hypotension. | 2002 May |
|
[Generic carbamazepine-induced subacute adrenal insufficiency?]. | 2002 Nov |
|
Dysautonomias: clinical disorders of the autonomic nervous system. | 2002 Nov 5 |
|
[Diabetic neuropathy--concept, staging, diagnosis, treatment]. | 2002 Oct |
|
Recently published papers: new evidence for old debates, new drugs and some timely reminders. | 2002 Oct |
|
Autonomic failure mimicing dopamine agonist induced vertigo in a patient with macroprolactinoma. | 2002 Oct |
|
Hyperaldosteronism: the internist's hypertensive disease. | 2002 Oct |
|
The mineralocorticoid receptor may compensate for the loss of the glucocorticoid receptor at specific stages of mammary gland development. | 2002 Sep |
|
A pilot randomized trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. | 2003 |
|
Neurocardiogenic syncope in children : current concepts in diagnosis and management. | 2003 |
|
Sepsis clinical knowledge: a role of steroid treatment. | 2003 Apr |
|
Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction? | 2003 Apr |
|
Diminished renal kallikrein responses to mineralocorticoid stimulation in African Americans: determinants of an intermediate phenotype for hypertension. | 2003 Apr |
|
Monozygotic twins with congenital adrenal hyperplasia: long-term endocrine evaluation and gene analysis. | 2003 Apr-May |
|
Association between supine hypertension and orthostatic hypotension in autonomic failure. | 2003 Aug |
|
Primary aldosteronism and hypertensive disease. | 2003 Aug |
|
Recently published papers: a number of treatment controversies. | 2003 Feb |
|
Chronic fatigue syndrome and Addison's disease. | 2003 Feb |
|
Successful treatment of severe orthostatic hypotension with erythropoietin. | 2003 Jan |
|
[Investigation of hyperaldosteronism in the hypertensive patient. Why? When? How?]. | 2003 Jan |
|
Drug treatment of orthostatic hypotension and vasovagal syncope. | 2003 Jan-Feb |
|
Treating interdialytic hyperkalemia with fludrocortisone. | 2003 Jan-Feb |
|
Serum leptin levels in patients with 21-hydroxylase deficiency before and after treatment. | 2003 Jan-Mar |
|
Automated coupling of capillary-HPLC to matrix-assisted laser desorption/ionization mass spectrometry for the analysis of small molecules utilizing a reactive matrix. | 2003 Jul |
|
Neurologic complications following treatment of canine hypoadrenocorticism. | 2003 Jun |
|
Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. | 2003 Jun |
|
[A 47-year-old man with "pure autonomic failure" and pernicious anemia]. | 2003 Jun 13 |
|
Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study. | 2003 Jun 15 |
|
Stability of fludrocortisone acetate solutions prepared from tablets and powder. | 2003 Mar |
|
Parkinsonism associated with Addison's disease. | 2003 Mar |
|
Granulomatous interstitial nephritis. | 2003 Mar |
|
Congenital adrenal hypoplasia presenting as a chronic respiratory condition. | 2003 Mar |
|
Simultaneous quantification of budesonide and its two metabolites, 6beta-hydroxybudesonide and 16alpha-hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry. | 2003 Mar-Apr |
|
Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency. | 2003 Mar-Apr |
|
Hyperpigmentation mimicking Laugier syndrome, levodopa therapy and Addison's disease. | 2003 May |
|
Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report. | 2003 May |
|
Corticosteroid insufficiency in acutely ill patients. | 2003 May 22 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:17:57 GMT 2023
by
admin
on
Fri Dec 15 15:17:57 GMT 2023
|
Record UNII |
V47IF0PVH4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C1103
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
V47IF0PVH4
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
FLUDROCORTISONE ACETATE
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS; slightly soluble in ether R. Category: Adrenal hormone. Storage: Fludrocortisone acetate should be kept in a well-closed container, protected from light. Additional information: Fludrocortisone acetate is hygroscopic. Definition: Fludrocortisone acetate contains not less than 96.0% and not more than 104.0% of C23H31FO6, calculated with reference to the dried substance. | ||
|
V47IF0PVH4
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
15186
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
1191
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
DTXSID2023062
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
208-180-4
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
225609
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
514-36-3
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201010
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
5102
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
1273003
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
m5431
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB02209MIG
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
DBSALT000659
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
100000092613
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | |||
|
165516
Created by
admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|